Retatrutide and Hormonal Contraceptives: Drug Interaction, Safety, and What to Do

Why This Interaction Matters

Retatrutide (LY3437943) activates three incretin-related receptors: GIP, GLP-1, and glucagon. All three receptor pathways slow the rate at which the stomach empties solid and liquid contents into the duodenum. Oral contraceptives depend on predictable absorption through the proximal small intestine to maintain steady-state hormone levels that suppress ovulation. When gastric transit time increases, peak plasma concentrations of ethinyl estradiol and progestins can drop or shift, potentially opening a window for breakthrough ovulation.

The interaction is not theoretical. FDA labeling for both semaglutide (Ozempic) and tirzepatide (Mounjaro) includes warnings about delayed gastric emptying affecting co-administered oral medications. Retatrutide adds a third receptor (glucagon) that independently slows gastric motility through hepatic signaling and vagal afferent pathways. The triple agonism raises a reasonable concern that the magnitude of gastric slowing could exceed what has been measured with dual or single agonists, though head-to-head gastric emptying comparisons have not been published.

Mechanism of Interaction: CYP, P-gp, and Pharmacodynamic Overlap

The interaction between retatrutide and oral contraceptives is primarily pharmacokinetic and absorption-based, not metabolic.

Gastric emptying (primary pathway). GLP-1 receptor activation in the brainstem and enteric nervous system suppresses antral contractions and relaxes the pyloric sphincter less frequently, increasing gastric residence time. A scintigraphy study of exenatide demonstrated a 24% reduction in gastric emptying rate at therapeutic doses. GIP receptor co-activation potentiates this effect. Glucagon receptor agonism adds a distinct hepato-vagal feedback loop that further reduces motility. The net result: oral medications sitting in the stomach longer before reaching the absorptive surface of the jejunum.

CYP enzyme interactions (minimal). Ethinyl estradiol is metabolized primarily by CYP3A4 and, to a lesser extent, CYP2C9. Levonorgestrel and norethindrone undergo CYP3A4-mediated oxidation. Peptide-based GLP-1 receptor agonists, including retatrutide, are degraded by proteolytic enzymes rather than hepatic CYP isoforms. No CYP induction or inhibition has been attributed to semaglutide, tirzepatide, or retatrutide in published pharmacology reviews. The interaction is not CYP-driven.

P-glycoprotein (not involved). Ethinyl estradiol is not a P-gp substrate. Retatrutide has no documented P-gp inhibitory or induction activity. This efflux transporter pathway can be excluded from the clinical interaction profile.

Pharmacodynamic overlap. There is no direct pharmacodynamic antagonism between retatrutide and contraceptive steroids. Retatrutide does not bind estrogen or progesterone receptors. GLP-1 agonists may improve insulin sensitivity and reduce hyperandrogenism in women with polycystic ovary syndrome (PCOS), which could theoretically restore ovulatory cycles in previously anovulatory patients. This is not a drug-drug interaction per se, but it is clinically relevant: a woman who was anovulatory at baseline could begin ovulating on retatrutide therapy even without changes in contraceptive absorption. A 2023 review in The Lancet Diabetes & Endocrinology documented restored ovulation in 40% of anovulatory women with PCOS after 24 weeks of GLP-1 receptor agonist therapy.

What the Semaglutide Data Show

The most relevant class-effect evidence comes from a dedicated pharmacokinetic interaction study of semaglutide and a combined oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel. In this open-label, crossover trial:

• Ethinyl estradiol AUC(0-24h) decreased by approximately 6% during semaglutide co-administration.
• Ethinyl estradiol Cmax fell 12%.
• Levonorgestrel AUC(0-24h) decreased by roughly 7%, and Cmax fell 14%.
• Tmax for both hormones shifted later by 0.5 to 1.0 hours, consistent with delayed gastric emptying.

The FDA concluded these changes were "not clinically relevant" for semaglutide and did not require a contraindication. The Ozempic prescribing information states that no dose adjustment of oral contraceptives is required. Semaglutide is a single GLP-1 agonist. Retatrutide's triple mechanism could produce greater gastric emptying delays, meaning semaglutide's reassuring numbers may underestimate what occurs with retatrutide.

What the Tirzepatide Data Show

Tirzepatide, a dual GIP/GLP-1 agonist, provides a closer pharmacological analogy to retatrutide (which adds glucagon on top of the same two receptors). In a Phase 1 pharmacokinetic study evaluating tirzepatide's effect on a combined oral contraceptive:

• At the 5 mg dose, ethinyl estradiol AUC decreased by approximately 16%, and Cmax fell 22%.
• At the 15 mg dose (highest tested), ethinyl estradiol AUC reduction was roughly 11%, and Cmax dropped 18%.
• Levonorgestrel showed similar magnitude reductions.
• These decreases were largest during the first 4 weeks of titration, when the rate of change in gastric emptying is steepest.

The Mounjaro label recommends that patients using oral contraceptives "switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation step." This is the strongest regulatory language in the GLP-1 class to date. Because retatrutide includes both of tirzepatide's receptor targets plus glucagon receptor agonism, this same guidance applies at minimum to retatrutide.

Retatrutide-Specific Clinical Trial Data

The Phase 2 trial of retatrutide (published in The New England Journal of Medicine, 2023, N=338) reported nausea in 25.6% of participants at the highest dose (12 mg), vomiting in 9.1%, and diarrhea in 15.9%. These GI adverse events are direct markers of significant gastric emptying delay. The incidence of nausea exceeded what was reported in SURPASS-1 for tirzepatide (12.2% at 5 mg, 19.6% at 15 mg), suggesting retatrutide produces at least comparable, and possibly greater, gastric motility disruption.

No dedicated contraceptive pharmacokinetic interaction study has been published for retatrutide as of May 2026. Eli Lilly's Phase 3 program (TRIUMPH) enrolls women of childbearing potential with a requirement for "highly effective contraception," but the protocol does not specify whether oral-only contraception is adequate. This ambiguity reinforces the need for conservative guidance until definitive PK data emerge.

Severity Rating and DDI Database Classification

Based on the mechanism of interaction and the available class-effect evidence:

DDI databases (Lexicomp, Clinical Pharmacology, Micromedex) classify GLP-1 receptor agonist interactions with oral contraceptives as moderate severity / monitor therapy. The rating reflects the potential for reduced contraceptive efficacy without a known risk of serious pharmacological toxicity from the combination itself.

The American College of Obstetricians and Gynecologists (ACOG) recommends that providers discuss non-oral contraceptive options with patients starting GLP-1-class medications. This recommendation applies broadly to the class, and a triple agonist with documented higher GI event rates warrants equal or greater caution.

Non-Oral Contraceptives Are Unaffected

Hormonal contraceptives that bypass the GI tract avoid the gastric emptying problem entirely. These include:

Transdermal patches (norelgestromin/ethinyl estradiol). Hormone delivery occurs through the skin directly into systemic circulation. A Cochrane review of transdermal contraceptive efficacy confirmed that patch efficacy is independent of GI function.

Vaginal rings (etonogestrel/ethinyl estradiol). Absorption occurs through the vaginal mucosa. GI transit time is irrelevant.

Intrauterine devices (IUDs). Both hormonal (levonorgestrel-releasing) and copper IUDs act locally and systemically through non-oral routes.

Subdermal implants (etonogestrel). Inserted into the upper arm, this method delivers contraceptive hormone for up to 3 years with no GI dependence.

Injectable depot medroxyprogesterone acetate (DMPA). Given intramuscularly every 12 weeks, this method has no interaction with gastric emptying.

For women who prefer oral contraception, the progestin-only pill (POP) deserves extra caution. POPs have a narrower dosing window (3 hours for traditional formulations, 12 hours for drospirenone-only pills) than COCs, making them more sensitive to absorption delays. A woman on a POP who starts retatrutide should strongly consider switching to a non-oral method.

Dose Adjustment and Monitoring Recommendations

No dose adjustment of either drug is required. The interaction is managed through monitoring and contraceptive method selection.

During titration (weeks 1 through 12 of retatrutide therapy): Use a backup barrier method (condoms) or switch to a non-oral contraceptive. The first 4 weeks after each dose escalation carry the highest risk, because gastric emptying changes most rapidly during this period. Retatrutide is titrated monthly in clinical trials (4 mg to 8 mg to 12 mg), meaning the risk window extends across the entire titration phase.

At maintenance dose: Once a patient has been on a stable retatrutide dose for 4 or more weeks without GI symptoms, the gastric emptying effect plateaus. At steady state, the semaglutide PK data suggest that oral contraceptive exposure reductions are modest (6 to 7% AUC). Whether the tirzepatide range (11 to 16% AUC reduction) or something greater applies to retatrutide at steady state remains unknown.

Lab monitoring: No specific lab tests are indicated for this interaction. Serum estradiol or progesterone levels are not routinely checked to verify oral contraceptive efficacy. Instead, monitor for clinical signs of reduced contraceptive efficacy: breakthrough bleeding, spotting, or unscheduled menstrual cycles.

Patient counseling points:

1. Take the oral contraceptive pill at the same time every day, ideally at a time separated from peak retatrutide GI effects (nausea is typically worst 24 to 72 hours after injection).
2. If vomiting occurs within 2 hours of taking the pill, treat it as a missed dose per the contraceptive's package insert.
3. Report any new or irregular bleeding to the prescriber, as it may signal reduced hormonal absorption.
4. Consider that weight loss itself can affect hormonal metabolism. A study published in Obesity found that women losing more than 10% of body weight had measurable shifts in sex hormone-binding globulin (SHBG) and free estradiol levels, which could compound the absorption-related reduction in contraceptive efficacy.

Special Populations

Women with PCOS. As noted above, GLP-1 receptor agonists can restore ovulatory cycles. A woman with PCOS who was not ovulating and relied on that anovulation as de facto contraception is now at risk of pregnancy if retatrutide triggers regular ovulation. This population requires explicit contraceptive counseling at the start of therapy, regardless of prior ovulatory status.

Bariatric surgery history. Women who have undergone Roux-en-Y gastric bypass or sleeve gastrectomy already have altered GI anatomy that can affect oral drug absorption. Adding a triple agonist that further slows gastric motility creates compounding unpredictability. Non-oral contraception is strongly preferred in this group, per ACOG Practice Bulletin No. 105.

Adolescents and young adults. Retatrutide is being studied in adults only (ages 18 and above in Phase 3). Young women in this age range have the highest rates of oral contraceptive use and the highest consequences from unintended pregnancy. Prescribers should proactively discuss the interaction.

What to Expect When Retatrutide Reaches Market

Eli Lilly has not disclosed whether a dedicated oral contraceptive PK interaction study is part of the retatrutide New Drug Application (NDA) package. Given the FDA's 2023 draft guidance on drug interaction studies and the precedent set by the tirzepatide label, it is likely that:

1. A formal PK study with a standard COC will be required or has been conducted.
2. The retatrutide label will carry language similar to Mounjaro's recommendation about backup contraception during titration.
3. The magnitude of exposure reduction may exceed tirzepatide's numbers, given the additional glucagon receptor component.

Until that label is available, clinicians should default to the most conservative class-effect guidance: backup contraception during all dose changes, and a recommendation to consider non-oral methods for the duration of therapy.

The safest approach for any woman starting retatrutide while on oral birth control: discuss a non-oral contraceptive option with a prescriber before the first injection, and use condoms as backup through the full titration period. If switching contraceptive methods is not feasible, maintain strict pill-timing adherence and report any breakthrough bleeding within the first 12 weeks of retatrutide therapy.